Table II.
Results of the numbers of v-CTCs and the value of CEA in 8 patients undergoing SEMS insertion.
| v.CTC detection (cells) | CEA (ng/ml) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Sex/age | Stage (TNM) | Surgical methods | Period from stent insertion to resection (day) | Before-stent | After-stent (10 days later) | After-resection (30 days later) | Follow-up | Before-stent | After-resection | Adjuvant therapy (yes/no) | Recurrence (yes/no) |
| 1 | Male/77 | T3N0M0 (IIA) | S | 13 | 0 | 3; Vim(+):1 Vim and CK double positive:2 | 4; Vim(+):4 | 6; Vim(+):6 (POM 21) | 9.9 | 2.3 | Yes (UFT+LV) | Yes (Lymph nodes) |
| 2 | Male/69 | T3N2aM0 (IIIB) | S | 27 | 0 | 1; Vim(+):1 | 0 | NT | 91.4 | 3.7 | Yes (Xeloda) | No |
| 3 | Male/83 | T3N2bM0 (IIIC) | S | 15 | 0 | 0 | 0 | NT | 3.4 | 2.0 | No | No |
| 4 | Female/62 | T3N0M0 (IIA) | T | 13 | 1; Vim(+):1 | 1; Vim(+):1 | 14; Vim(+):13 CK(+):1 | 1; Vim(+):1 (POM 14) | 3.9 | 2.6 | No | No |
| 5 | Female/69 | T3N0M0 (IIA) | S | 14 | 19; Vim(+):19 | 21; Vim(+):21 | 12; Vim(+):12 | NT | 5.2 | 2.6 | Yes (UFT+LV) | No |
| 6 | Male/76 | T3N0M0 (IIA) | S | 19 | 0 | 0 | 0 | NT | 6.8 | 3.1 | No | No |
| 7 | Male/77 | T3N1bM0 (IIIB) | D | 25 | 1; Vim(+):1 | 0 | 1; Vim(+):1 | NT | 16.8 | 4.3 | Yes (UFT+LV) | No |
| 8 | Female/85 | T3N2aM0 (IIIB) | No surgery | 3; Vim(+):3 | 20; Vim(+):20 | NT | 35; Vim(+):22 Vim and CK double negative: 13 (16 months after stent) | 46.7 | NT | No | Yes (Liver) | |
v-CTCs, viable circulating tumor cells; CEA, carcinoembryonic antigen; SEMS, self-expanding metallic stent; S, Laparoscopic sigmoidectomy; D, Laparoscopic left colectomy; T, laparoscopic right hemicolectomy; NT, Not tested; POM, postoperative month; TNM, tumor node metastasis; Vim, vimentin; CK, cytokeratin; UFT, Tegarfur/uracil; LV, Leucovorin calcium.